Gavin David Clark
Direttore/Membro del Consiglio presso Lamellar Biomedical Ltd.
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Alec Mackie | M | - |
Lamellar Biomedical Ltd.
 Lamellar Biomedical Ltd. Pharmaceuticals: MajorHealth Technology Lamellar Biomedical Ltd. manufactures basic pharmaceutical products. The firm's offers lamellasomes, a synthetic substance that mimics the actions lamellar bodies and provides treatment for respiratory diseases, such as cystic fibrosis. The company was founded in 2006 and is headquartered in Bellshill, the United Kingdom. | - |
| Alec McLean | M | - |
Lamellar Biomedical Ltd.
Lamellar Biomedical Ltd. Pharmaceuticals: MajorHealth Technology Lamellar Biomedical Ltd. manufactures basic pharmaceutical products. The firm's offers lamellasomes, a synthetic substance that mimics the actions lamellar bodies and provides treatment for respiratory diseases, such as cystic fibrosis. The company was founded in 2006 and is headquartered in Bellshill, the United Kingdom. | - |
| Duncan Moore | M | 65 |
Lamellar Biomedical Ltd.
Lamellar Biomedical Ltd. Pharmaceuticals: MajorHealth Technology Lamellar Biomedical Ltd. manufactures basic pharmaceutical products. The firm's offers lamellasomes, a synthetic substance that mimics the actions lamellar bodies and provides treatment for respiratory diseases, such as cystic fibrosis. The company was founded in 2006 and is headquartered in Bellshill, the United Kingdom. | 11 anni |
| John Carney | M | - |
Lamellar Biomedical Ltd.
Lamellar Biomedical Ltd. Pharmaceuticals: MajorHealth Technology Lamellar Biomedical Ltd. manufactures basic pharmaceutical products. The firm's offers lamellasomes, a synthetic substance that mimics the actions lamellar bodies and provides treatment for respiratory diseases, such as cystic fibrosis. The company was founded in 2006 and is headquartered in Bellshill, the United Kingdom. | 11 anni |
| Christopher Thomas Wardhaugh | M | 54 |
Lamellar Biomedical Ltd.
Lamellar Biomedical Ltd. Pharmaceuticals: MajorHealth Technology Lamellar Biomedical Ltd. manufactures basic pharmaceutical products. The firm's offers lamellasomes, a synthetic substance that mimics the actions lamellar bodies and provides treatment for respiratory diseases, such as cystic fibrosis. The company was founded in 2006 and is headquartered in Bellshill, the United Kingdom. | 4 anni |
| Adam Bryson | M | - |
Lamellar Biomedical Ltd.
Lamellar Biomedical Ltd. Pharmaceuticals: MajorHealth Technology Lamellar Biomedical Ltd. manufactures basic pharmaceutical products. The firm's offers lamellasomes, a synthetic substance that mimics the actions lamellar bodies and provides treatment for respiratory diseases, such as cystic fibrosis. The company was founded in 2006 and is headquartered in Bellshill, the United Kingdom. | - |
| Alastair Innes | M | - |
Lamellar Biomedical Ltd.
Lamellar Biomedical Ltd. Pharmaceuticals: MajorHealth Technology Lamellar Biomedical Ltd. manufactures basic pharmaceutical products. The firm's offers lamellasomes, a synthetic substance that mimics the actions lamellar bodies and provides treatment for respiratory diseases, such as cystic fibrosis. The company was founded in 2006 and is headquartered in Bellshill, the United Kingdom. | - |
| Steven Porteous | M | - |
Lamellar Biomedical Ltd.
Lamellar Biomedical Ltd. Pharmaceuticals: MajorHealth Technology Lamellar Biomedical Ltd. manufactures basic pharmaceutical products. The firm's offers lamellasomes, a synthetic substance that mimics the actions lamellar bodies and provides treatment for respiratory diseases, such as cystic fibrosis. The company was founded in 2006 and is headquartered in Bellshill, the United Kingdom. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Landon Clay | M | 98 |
GlycoForm Ltd.
 GlycoForm Ltd. Pharmaceuticals: MajorHealth Technology Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK | - |
| Elizabeth Phelps | F | - |
GlycoForm Ltd.
GlycoForm Ltd. Pharmaceuticals: MajorHealth Technology Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK | - |
| Mario Polywka | M | 61 |
GlycoForm Ltd.
GlycoForm Ltd. Pharmaceuticals: MajorHealth Technology Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK | 7 anni |
| Melanie Lee | M | 65 |
GlaxoWellcome /Pharmocology Unit/
| 10 anni |
| Louis Joseph Nisbet | M | - |
GlycoForm Ltd.
GlycoForm Ltd. Pharmaceuticals: MajorHealth Technology Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK | - |
| Benjamin Guy Davis | M | 54 |
GlycoForm Ltd.
GlycoForm Ltd. Pharmaceuticals: MajorHealth Technology Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK | 9 anni |
| Chris Urch | M | - |
GlycoForm Ltd.
GlycoForm Ltd. Pharmaceuticals: MajorHealth Technology Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK | 7 anni |
| Antony J. Fairbanks | M | - |
GlycoForm Ltd.
GlycoForm Ltd. Pharmaceuticals: MajorHealth Technology Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK | 9 anni |
| James Mallinson | M | 63 |
GlycoForm Ltd.
GlycoForm Ltd. Pharmaceuticals: MajorHealth Technology Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK | - |
| Heather Giles | M | - |
GlaxoWellcome /Pharmocology Unit/
| 5 anni |
| David Hughes Scales | M | - |
GlycoForm Ltd.
GlycoForm Ltd. Pharmaceuticals: MajorHealth Technology Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK | 3 anni |
| Phillip Dolamore | M | - |
GlycoForm Ltd.
GlycoForm Ltd. Pharmaceuticals: MajorHealth Technology Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK | - |
| David Colpman | M | 62 |
GlaxoWellcome /Pharmocology Unit/
| 2 anni |
| Stefan Prebil | M | 62 |
GlaxoWellcome /Pharmocology Unit/
| 3 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Regno Unito | 22 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Gavin David Clark
- Contatti personali
